Overview

FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

To assess safety, tolerability, PK, preliminary efficacy and determine recommended phase 2 dose (RP2D) of JAB-21822 administered in adult participants with KRAS p.G12C-mutant advanced solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Jacobio Pharmaceuticals Co., Ltd.